3DNA

Code Biotherapeutics is a biotechnology company pioneering a novel class of non-viral genetic medicines through its proprietary 3DNA platform. The 3DNA technology employs a multivalent, synthetic DNA scaffold designed to deliver large genetic payloads—including whole genes and RNAi—with high cell-specific targeting and the potential for re-dosing, overcoming the immunogenicity and size constraints of viral vectors. The company is advancing an internal pipeline focused on Duchenne Muscular Dystrophy (DMD) and Type 1 Diabetes (T1D), while also collaborating with Takeda on programs for rare liver and CNS diseases. Based in the Greater Philadelphia area, Code Bio is supported by a strong syndicate of investors including Northpond Ventures, Amgen Ventures, and Takeda Ventures.